Perlara
ActivePerlara: building the YC for rare disease parents
This company has previously operated under “Perlstein Lab PBC”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively. Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech
Founders
No founder data available for this company.
Related startups
Using the immune system to cure disease
Democratizing gene therapy by reinventing its manufacturing and…
